Highlights
-
New agreement with TasAlk secures the supply of high-quality cannabis resin to AusCann
-
Resin supply to be used for future production and development of AusCann’s cannabinoids-based pharmaceutical product line
-
Enables AusCann to further de-risk its supply chain with a smaller number of core GMP suppliers of high-quality resin
-
Supports AusCann’s strategy to deliver reliable, dose-controlled cannabinoids-based medicines to doctors and patients for improved patient health outcomes
1 July 2019 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to announce it has signed a new supply agreement for the purchase of cannabis resin from Tasmanian Alkaloids (TasAlk). TasAlk is one of the world’s largest manufacturers of controlled substances producing alkaloid raw material in Tasmania for medicinal purposes. Medicinal Cannabis products will be added to this portfolio with analytical testing, cultivation and manufacturing services available in early 2020.
For further information please download the attached PDF:
Download this document
